A b s t r a c t
We reviewed our institutional experience with de novo CD5+, large B-cell lymphomas to determine whether they represent a distinct entity and are related to CD5+ small B-cell disorders. We identified 13 cases with multiparameter flow cytometry over a period of 58 months (5% of large B-cell lymphomas) in 7 females and 6 males. Three groups were identified. Group 1 (2 cases) had diffuse splenic red pulp involvement with a distinctive cordal pattern of infiltration, no other clinical evidence of mass disease, microscopic disseminated disease on further workup, and an identical immunoglobulin-negative immunophenotype. Group 2 cases (7 cases) were clinically and morphologically heterogeneous and had an immunophenotype resembling mantle cell lymphoma (FMC7-positive, CD23-). Group 3 (4 cases) had miscellaneous immunophenotypes, including one closely resembling chronic lymphocytic leukemia. Cyclin D1 was positive in only 1 of 10 evaluable cases (group 2). We conclude that CD5+ diffuse large B-cell lymphomas are heterogeneous; most cases do not seem to be related to chronic lymphocytic leukemia or mantle cell lymphoma. However, we identified a subgroup of primary splenic CD5+ large B-cell lymphoma with diffuse red pulp involvement and believe this may represent a distinct clinicopathologic entity.
Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous category on the basis of clinical, morphologic, immunophenotypic, and molecular features. 1 While the National Cancer Institute Working Formulation and the updated Kiel classification subdivide these tumors on the basis of morphologic features, the Revised European and American Lymphoma Classification and the World Health Organization classifications do not distinguish between subcategories of DLBCL, with a few specific exceptions such as mediastinal large B-cell lymphoma, and primary effusion lymphoma. [1] [2] [3] [4] None of the currently used classification systems distinguish among DLBCLs on the basis of immunophenotype.
CD5 is a 67-kd lymphocyte antigen that is found primarily on T cells, but it also is expressed on small subsets of normal B cells. 5 Among B-cell malignant neoplasms, CD5 is found primarily on the cells of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and mantle cell lymphoma (MCL). However, a small proportion of large Bcell lymphomas have been found to express this antigen. [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] While some of these may represent large cell transformations of CLL/SLL or, rarely, MCL, [13] [14] [15] a history of antecedent small B-cell lymphoma is not present in many cases. However, lack of a previous diagnosis of lymphoma does not rule out the rare de novo large cell variant of MCL. 13 The purpose of the present study was to review our experience with de novo CD5+ DLBCLs with the aim of addressing the following questions: (1) Are these lesions related to CLL/SLL or MCL? (2) Do they represent a distinct clinicopathologic entity? In addition to a detailed clinical, morphologic, and immunophenotypic analysis, we assessed expression of cyclin D1 and p53 proteins, the latter because of the reported association of mutations in the p53 gene with transformed lymphoma. [18] [19] [20] 
Immunophenotyping
Fresh tissue samples were minced with a sterile scalpel blade, followed by passage through mesh (<100 µm) using a Pasteur pipette and suspension in 50 mL of Hanks buffered salt solution. This suspension was centrifuged at 1,200 rpm for 8 minutes, and the supernatant was decanted.
If RBC lysis was needed, the pellet was resuspended in 10 mL of ammonium chloride lysis solution, followed by an additional 8 minutes of centrifugation. After decanting the supernatant, the cell pellet was suspended in 30 mL of Hanks buffered salt solution. After another 8-minute centrifugation, the cell pellet was resuspended with an appropriate amount of 5% newborn calf serum in RPMI 640 media (Bio Whittaker, Walkersville, MD). Because of a large number of nonviable cells in 2 of the specimens (cases 6 and 12), they each underwent density gradient separation. The cells were underlaid with 10 mL of Histopaque-1077 (Sigma Diagnostics, St Louis, MO), with subsequent centrifugation for 25 minutes at 1,200 rpm. The mononuclear cell layer was removed and resuspended in 5% newborn calf serum in RPMI. For staining of surface antigens 0.1 to 0.75 × 10 6 cells were washed with a 0.1% phosphate-buffered saline-bovine serum albumin-sodium azide (PAB) buffer. The appropriate amounts of commercial direct-conjugated antibodies were added to the mixture ❚Table 1❚ and incubated at 2°C to 8°C in darkness for 20 minutes. After another PAB wash, 0.25 mL of paraformaldehyde was added to the reaction mixture. For intracellular antigens, before antibody incubation, 0.3 to 0.75 × 10 6 cells were incubated with 0.5 mL of 0.25% saponin for 10 minutes on ice followed by 2 PAB washes. Specimens were analyzed using 3-color (9 patients) or 4-color (4 patients) antibody panels ❚Table 2❚. The specimens were run on a FACScan (3-color) or a FACSCalibur (4-color) flow cytometer (Becton Dickinson Immunocytometry Systems, San Jose, CA) and analyzed with Paint-A-Gate software (Verity House, Topsham, ME). In some instances, additional antibody combinations were used at the discretion of the pathologist at the time of analysis. In 1 instance (case 8), limited material precluded full analysis. No gating was performed, and, thus, all normal and neoplastic populations within a given sample were analyzed. Antigen expression on abnormal populations was compared with appropriate isotypic controls and negative and positive populations in a given tube. In general, antigen positivity was defined as a discrete population shift relative to the isotypic control. Assessments of intensity of antigen expression were qualitative and based on accumulated laboratory experience with individual antibodies in normal and neoplastic cell populations.
Immunohistochemistry
Immunohistochemistry was performed on all cases with available paraffin blocks or unstained sections using a standard avidin-biotin-peroxidase method. Staining was performed for cyclin D1 expression (AM29, 1:75, Zymed Laboratories, San Francisco, CA) after antigen retrieval consisting of 9-minute pressure cooker incubation in a 0.25-mol/L concentration of tris(hydroxymethyl)aminomethane buffer, pH 9.0, and antibody incubation for 30 minutes at 37°C. Staining was performed for p53 (DO7, 1:50; DAKO, Carpinteria, CA) after antigen retrieval using a patented antigen retrieval citra protocol (Biogenex, San Ramon, CA) and 25-minute antibody incubation at room temperature. After staining, only the cases with nuclear positivity within the section (eg, endothelial cells for cyclin D1) were considered evaluable. Cases were considered positive for p53 protein expression if more than 5% of tumor cell nuclei were stained.
Results
Thirteen cases of de novo CD5+ DLBCL were identified, representing approximately 5% of DLBCLs analyzed during the same time period. Patient characteristics, including sites of presentation, clinical stage, and clinical course, are provided in ❚Table 3❚. The 13 patients were 7 females and 6 males ranging in age from 15 to 79 years (mean, 66 years). Ten of 13 patients were older than 60 years.
The intensity of CD5 expression was heterogeneous ❚Figure 1❚. In 6 cases (cases 1, 3, 4, 7, 12, and 13), the level of expression was similar to or slightly less than that seen in normal T cells (complete or nearly complete overlap of the populations on the basis of CD5) ( Figure 1A ). In 5 cases (cases 2, 5, 6, 8, and 10), the CD5 expression in the tumor cells showed only partial overlap with normal T cells but was clearly distinct from the negative populations ( Figure  1B ). In 1 case (case 9), CD5 expression was dim, showing substantial overlap with the negative populations ( Figure  1C ). However, the neoplastic population in this case was clearly shifted compared with the isotypic control. In addition, more than 20% of the neoplastic cells exceeded the 99th percentile of fluorescence for the same cell population in the appropriate isotypic control. Finally, in 1 case (case 11) the majority of tumor cells seemed to be negative for CD5, but a distinct subpopulation, representing approximately 10% of the tumor cells, expressed CD5 with an intermediate intensity between negative populations and normal T cells ( Figure 1D ). This subpopulation was clearly CD19+ and CD3-. The cases were divided into 3 groups on the basis of clinical presentation and immunophenotype, as shown in Table 3 and ❚Table 4❚. Group 1 cases (n = 2) were distinctive because they had isolated splenomegaly and lacked surface and cytoplasmic immunoglobulin. The lymphoma in groups 2 and 3 manifested in extrasplenic sites; these cases were differentiated on the basis of immunophenotype. 
Monoclonal kappa/monoclonal lambda/CD5/CD19 CD5/CD19/CD3
Polyclonal lambda/polyclonal kappa/CD20/CD38 FMC7/CD23/CD19 Monoclonal kappa/monoclonal lambda/CD19 Polyclonal lambda/polyclonal kappa/CD38 APC, allophycocyanin; CD, cluster designation; FITC, fluorescein isothiocyanate; PE, phycoerythrin; PerCP, peridinin chlorophyll. cases (n = 7) expressed FMC7 and lacked CD23, thus resembling in those respects MCL, whereas cases in group 3 (n = 4) demonstrated other miscellaneous patterns of antigen expression.
Group 1

Clinical Features
This group was composed of 2 men aged 64 and 68 years. These patients were distinctive because they had isolated splenomegaly with no other evidence of disease by physical examination or imaging studies. The lymphomas in both were classified as stage IV, however, by further workup. Bone marrow involvement was detected in 1 patient (case 1) at presentation. The other (case 2) had involvement of peripheral blood at the time of staging but a negative marrow examination. A liver biopsy was positive for lymphoma in case 1, and a liver biopsy and a splenic hilar lymph node biopsy revealed minimal involvement by lymphoma in case 2. One patient (case 1) achieved complete remission with conventional chemotherapy but experienced relapse at 22 months and died of disease at 24 months. The other was lost to follow-up shortly after diagnosis.
Immunophenotypic Features
The 2 cases in this group showed a uniform immunophenotypic profile (Table 4 ). Both were positive for FMC7, negative for CD23, brightly positive for CD20 and CD38, positive for CD19, and negative for CD10. In addition, both cases lacked both cytoplasmic and surface immunoglobulin. CD11c was positive in the 1 case tested, CD22 was positive in 1 of 2, and CD30 was negative in both cases. An additional unusual feature of case 1 was the presence of bright CD4 on the tumor cells. Both cases were negative for cyclin D1 and neither overexpressed p53 protein. 
Pathologic Features
Spleen.-The spleen in both cases was enlarged with masses of 950 and 1,000 g. Neither demonstrated dominant mass lesions. One spleen was described as showing no gross lesions whatsoever (case 2), whereas the other (case 1) was described as showing diffuse hemorrhagic cream-colored nodules throughout the entire specimen. Microscopically, both cases demonstrated exclusive red pulp infiltration. This was essentially diffuse, although areas without involvement could be identified focally in each case. The white pulp was not involved in either case and tended to appear inactive or atrophic. The nodularity noted grossly in case 1 corresponded to areas of greater and lesser red pulp involvement; the nodules were not related to the white pulp. While solid sheets of tumor cells with effacement of splenic architecture were present in each case ❚Image 1❚, both demonstrated a striking cordal pattern of infiltration ❚Image 2❚ and ❚Image 3❚. In case 1, the tumor cells were packed closely together, with a streaming, sometimes vaguely storiform pattern, producing a sarcomatoid appearance (Image 1). The tumor cells in case 2, on the other hand, tended to be more discohesive and loosely arranged Peripheral Blood.-Few (<1%) circulating lymphoma cells were present in case 2 at the time of splenectomy. These were large with round to slightly irregular nuclei, coarse chromatin, one to several distinct nucleoli, and moderately abundant, deeply basophilic cytoplasm ❚Image 5❚. Rare multinucleated tumor cells were present.
Bone Marrow.-The involved bone marrow trephine biopsy in case 1 demonstrated scattered, generally wellcircumscribed, nonparatrabecular aggregates containing large cells with cytologic features similar to those seen in the spleen. The bone marrow core biopsy and clot sections of case 2 demonstrated rare cells suggestive of lymphoma but no definite evidence of marrow involvement, despite the presence of circulating lymphoma cells in the blood.
Group 2
Clinical Features
This group included 2 men and 5 women ranging in age from 59 to 78 years ( Table 3 ). The lymphomas in 2 patients were classified as clinical stage I (1 stage IE), 1 as stage IIE, 1 as stage III, and 3 as stage IV. Three patients had widespread lymphadenopathy; one of these in addition had a prominent tonsillar mass. Three patients had localized lymph node enlargement. One of these, a patient with axillary nodal involvement, also had an ipsilateral breast mass presumed to represent lymphoma; the breast mass was not biopsied but resolved with chemotherapy. The last patient had nasal mucosal masses without lymph node involvement. The bone marrow was involved in 2 of the 6 patients known to have been evaluated at presentation. Six of 7 patients achieved complete remission with therapy; 1 achieved only a partial remission. Follow-up revealed that 4 patients were alive with no evidence of disease 15 to 31 months from diagnosis, although one of these was in the third remission after 2 relapses. Two died of disease at 11 and 14 months, and the patient who achieved a partial remission was alive with persistent disease at 4 months.
Immunophenotypic Features
By definition, all cases in this group were FMC7 positive and CD23- (Table 4 ). In addition, all seven cases expressed CD19, lacked CD10 and expressed moderate or bright CD20. CD38 was positive in 6 of 7, CD22 in 3 of 3, CD11c in 3 of 4, and CD30 in 0 of 3 cases. Six of 7 cases expressed surface immunoglobulin; 5 of these were moderate or bright intensity. Tissue was available for cyclin D1 evaluation in all 7 cases; of these, 2 were considered uninformative owing to absence of internal positive controls. Of the remaining 5, only 1 case demonstrated strong nuclear expression of cyclin D1 (case 6). This was the patient who died of disease 11 months after diagnosis. Five of 6 cases overexpressed p53, although in 2 cases, the percentage of positive cells barely exceeded the 5% threshold. The single negative case was the one that expressed cyclin D1.
Pathologic Features
The morphologic features in the group 2 cases were variable. All demonstrated a diffuse architecture; 1 case in addition showed areas of sinusoidal infiltration (case 5). None showed residual germinal centers within the infiltrate. Coagulative necrosis was present in only 1 case (case 6). The mitotic rate varied but was generally moderate to high. Two cases (7 and 8) contained numerous macrophages with ingested apoptotic debris. Tumor cell cytology was variable across cases. Uniform centroblastic morphologic features were seen in 1 case (case 4) and a pleomorphic centroblastic appearance in 3 (cases 3, 7, and 9). One case (case 8) was composed of polylobated tumor cells. This was the case with bone marrow involvement; the marrow infiltrates were scattered and interstitial and were composed of the same cells present in the lymph node. The case that demonstrated sinusoidal infiltration (case 5) had a polymorphous immunoblastic appearance, often with abundant cytoplasm, closely resembling anaplastic large cell lymphoma in some areas. Other areas of this tumor demonstrated pleomorphic tumor cells embedded in abundant collagen producing a sarcomatoid appearance. This case was CD30-. Finally, the case with cyclin D1 expression (case 6) was composed of a uniform proliferation of medium to large cells with regular round to oval nuclei, stippled chromatin, and distinct, often multiple nucleoli ❚Image 6❚.
Group 3
Clinical Features
This group consisted of 2 males and 2 females ranging in age from 15 to 79 years ( Table 3 ). The 15-year-old patient (case 12) had congenital HIV infection. The lymphoma in 2 patients was classified as stage I, 1 as stage II, and 1 as stage IV. Two patients had generalized lymphadenopathy, one accompanied by multiple skin nodules. One patient had involvement of multiple retroperitoneal lymph node sites. The last had isolated left inguinal adenopathy. The bone marrow was positive in 1 of 3 patients. Three patients achieved complete remission with chemotherapy; one (the HIV-positive patient) was not treated. Two patients were alive with no evidence of disease at 58 and 19 months; the latter was treated for a presumed intracranial relapse (no biopsy performed) with local radiotherapy. One patient was alive with disease at 44 months after several relapses. The HIV-positive patient who was not treated died within 1 week.
Immunophenotypic Features
These cases were heterogeneous immunophenotypically (Table 4) . Case 13 had a phenotype resembling CLL/SLL, with relatively bright CD23 with only dim FMC7, lack of CD38, and dim to moderate intensity surface immunoglobulin expression. Cases 11 and 12 lacked CD23 and FMC7 and were dim positive for CD20 and surface immunoglobulin. Finally, case 10 was distinguished by dim expression of CD10; CD23 and FMC7 were not assessed in this case owing to limited material. All 3 cases with available blocks were negative for cyclin D1. Three of 3 cases overexpressed p53 protein; in 2 cases, including the case with an immunophenotype resembling CLL/SLL (case 13), p53 stained only a small percentage of cells.
Morphologic Features
Cases 11 and 12 demonstrated diffuse effacement of architecture without residual normal lymph node structures, whereas case 10 showed partial nodal involvement with compressed rims of normal lymph node. Case 13 showed scattered residual germinal centers with intact mantle zones scattered within what was otherwise a diffusely effacing large cell infiltrate. Cytologically, cases 11 and 12 demonstrated uniform to slightly pleomorphic centroblastic morphologic features. In contrast, case 10 had a polylobated immunoblastic appearance. Finally, case 13, which had an immunophenotype similar to CLL, demonstrated variably irregular large cells with delicate chromatin and nuclear membranes and small but distinct nucleoli. They did not resemble prolymphocytes or paraimmunoblasts.
Discussion
We have presented our institutional experience with de novo CD5+ DLBCL. These cases represented approximately 5% of large B-cell lymphomas analyzed in our flow cytometry laboratory, compared with the 8% reported by Burns et al 12 and the 10% reported by Taniguchi et al 8 and Yamaguchi et al. 21 Although overall the CD5+ DLBCLs were not clinically or pathologically distinctive, a subgroup of 2 patients (group 1) exhibited a unique clinicopathologic profile. Both patients had isolated splenomegaly without other evidence of mass disease on imaging studies or physical examination. However, both had systemic disease on further workup (peripheral blood or bone marrow in both, liver in both, splenic hilar lymph node in one). Both cases lacked dominant mass lesions in the spleen and showed exclusive red pulp involvement with a striking cordal distribution. These findings contrast with the usual appearance of large cell lymphoma manifesting in the spleen as large mass lesions or, less commonly, with diffuse white pulp involvement. 22, 23 The cases also had a uniform immunophenotype: FMC7 positive, CD23-, bright CD20+, bright CD38+, p53 negative, and surface and cytoplasmic immunoglobulin negative. This last feature is particularly interesting given that only 3.4% of B-cell non-Hodgkin lymphomas have been reported to lack surface light chain expression. 24 The features of these splenic cases suggest that they are not related to the 2 common types of CD5+ B-cell lymphoma, CLL/SLL and MCL. Because they demonstrate large cell lymphoma histologic features, they do not resemble either of these diseases in their classic forms. Therefore, they must be distinguished from unusual or transformed variants of CLL/SLL and MCL. Both cases demonstrated an immunophenotype more closely resembling MCL than CLL/SLL. However, both were negative for cyclin D1, making it unlikely that these cases represented a variant of MCL. Furthermore, primary clinical manifestation in the spleen is highly unusual for MCL. 25 When it occurs, it shows a predominant white pulp pattern of involvement, 26 in contrast with the cases in our series that showed exclusively red pulp involvement. In regard to the distinction from large cell transformation of CLL, our experience is that these maintain an immunophenotype resembling CLL (CD23+, FMC7 negative). 27 In addition, neither of these patients had clinical or pathologic evidence of preexisting CLL/SLL. Diffuse red pulp involvement by DLBCL has been reported, but is an uncommon pattern. [28] [29] [30] [31] Of 21 primary and secondary large B-cell lymphomas involving the spleen reported by Arber et al, 23 2 had diffuse red pulp involvement; detailed immunophenotyping was not reported in these cases. Three cases with clinicopathologic features similar to those in the present series have been reported in the literature. 29, 30 These occurred in patients ranging from 42 to 72 years of age, each with splenomegaly without other clinically evident disease. All 3 cases demonstrated diffuse red pulp involvement; as in our patients, this was limited to the splenic cords. Finally, each had peripheral blood and bone marrow involvement. An unusual feature of the 2 cases reported by Palutke et al 29 was that the lymphoma cells exhibited phagocytic activity; we did not observe this in our cases. CD5 was only assessed in the case of Salgado et al 30 and was found to be positive. Thus, it seems that these tumors may represent the same entity as in our patients.
Among published series of CD5+ DLBCL, splenic involvement was reported in 4 of 25 cases in the series of Yamaguchi et al. 21 All 4 involved other extranodal and nodal sites, and the pattern of infiltration was not described. 8 Yatabe et al 9 reported splenomegaly in 4 of 8 cases in which information about the spleen was available. None were described as having isolated splenomegaly, although insufficient data were provided to rule out this possibility entirely in individual cases. 9 Harada et al 32 reported the spleen as the major site of manifestation in 1 of 11 CD5+ DLBCLs, but other details were not provided.
CD5 expression has been reported in a subset of intravascular large B-cell lymphomas. 11 This is interesting, given the presence of sinusoidal infiltration of lymph node and liver in one of the patients with splenic lymphoma in our series. However, of the 5 CD5+ intravascular B-cell lymphomas reported by Khalidi et al, 11 none was described as producing splenomegaly. Furthermore, we did not find an intravascular pattern in the spleen in either of our cases.
In contrast with the group 1 splenic cases, the remaining cases (groups 2 and 3) had no distinctive morphologic or clinical features. These patients were generally elderly (mean age, 65.5 years) and showed a female predominance (7 of 11). The most common manifestation was isolated or multifocal lymphadenopathy. The clinical course of these patients was generally favorable: 6 were alive with no evidence of disease from 15 to 59 months from diagnosis, although 2 patients required treatment for relapsed disease. Two patients were alive with disease at 4 and 44 months. Three patients died of disease at 1 week, 11 months, and 14 months. The patient who died at 1 week was the only pediatric case in the series, as well as the only patient infected with HIV; he received no therapy.
Similar to our study, the patients in published series of de novo CD5+ DLBCL also have been in older age groups, with an overall mean age of 65 years. 6, 9, 21, 32 21 However, Harada et al 32 demonstrated a significantly decreased overall survival and a higher incidence of bone marrow involvement in CD5+ DLBCL compared with CD5-cases (P = .016).
The most common immunophenotype of the 11 extrasplenic tumors was one that resembled MCL (group 2, 7 cases), with expression of FMC7 without CD23 and moderate to bright expression of CD20. 34 Six of these cases expressed CD38, also characteristic of MCL. 35 This immunophenotype raises the question of whether these cases represent the rare large cell variant of MCL, specifically the "transformed" type as defined by Zoldan et al. 13 Of the group 2 cases, only 1 expressed cyclin D1, thus prompting a diagnosis of large cell variant of MCL. Notably, this patient had the most aggressive clinical course in group 2 and died of lymphoma in 11 months, consistent with the reported behavior of this rare variant. 13 Of the 6 remaining group 2 patients, 4 had evaluable cyclin D1 studies, all of which were negative. Furthermore, none contained areas of more typical MCL or exhibited a mantle zone pattern of infiltration, as described by Zoldan et al. 13 No cyclin D1 expression was found in 20 cases of de novo CD5+ DLBCL in the 2 previous studies in which this was evaluated. 8, 9 Previous studies showing extensive somatic hypermutation in de novo CD5+ DLBCL also support the contention that the majority of these tumors are not related to MCL. 7, 8 Group 3 included 4 cases with miscellaneous immunophenotypic features. Only 1 case expressed CD23. As mentioned previously, our experience is that large cell transformations of CLL/SLL retain a CLL/SLL phenotype, with expression of CD23 and a lack of FMC7. 27 Thus, on an immunophenotypic basis, we have found little evidence that these CD5+ DLBCLs are related to CLL/SLL. Of interest, though, the CD23-expressing case also had other immunophenotypic features suggestive of CLL/SLL (relatively dim SIg and FMC7). However, there was no clinical, hematologic, or pathologic evidence of preexisting CLL/SLL in this patient. Matolcsy et al 6 and Taniguchi et al 8 documented CD23 expression in 0 of 8 CD5+ and 2 of 13 DLBCLs, respectively.
The high rate of p53 protein expression in groups 2 and 3 is of interest (8 of 9 evaluable cases), given the high rate of p53 expression seen in transformed and aggressive variants of MCL. 13, 36 Ironically, the one negative case was the cyclin D1-expressing tumor. Expression of p53 also has been associated with Richter syndrome. 15, 18 To our knowledge, p53 protein expression has not been assessed in de novo CD5+ DLBCLs, although Matolcsy et al 6 found no p53 gene mutations among nine cases.
CD5+ diffuse large B-cell lymphomas are heterogeneous and in most instances do not seem to be related to CLL/SLL or MCL. However, we identified 2 distinctive cases that manifested primarily in the spleen with a striking cordal pattern of red pulp infiltration. In addition, each of these subclinically involved liver and blood or bone marrow and had an identical immunophenotype that was notable for lack of surface or cytoplasmic immunoglobulin. While we believe that the anatomic distribution and immunophenotype suggest that these represent a distinct clinicopathologic entity, analysis of additional cases will be necessary to confirm this impression.
